Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Total Liabilities (2016 - 2026)

Avanos Medical's Total Liabilities history spans 13 years, with the latest figure at $295.5 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 9.27% to $295.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $295.5 million, a 9.27% decrease, with the full-year FY2025 number at $295.5 million, down 9.27% from a year prior.
  • Total Liabilities hit $295.5 million in Q4 2025 for Avanos Medical, up from $289.7 million in the prior quarter.
  • Over the last five years, Total Liabilities for AVNS hit a ceiling of $511.7 million in Q3 2022 and a floor of $262.7 million in Q2 2025.
  • Historically, Total Liabilities has averaged $401.8 million across 5 years, with a median of $429.2 million in 2023.
  • Biggest five-year swings in Total Liabilities: soared 52.29% in 2022 and later crashed 39.72% in 2025.
  • Tracing AVNS's Total Liabilities over 5 years: stood at $333.0 million in 2021, then surged by 48.86% to $495.7 million in 2022, then decreased by 7.99% to $456.1 million in 2023, then dropped by 28.59% to $325.7 million in 2024, then decreased by 9.27% to $295.5 million in 2025.
  • Business Quant data shows Total Liabilities for AVNS at $295.5 million in Q4 2025, $289.7 million in Q3 2025, and $262.7 million in Q2 2025.